{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:33:59Z","timestamp":1793050439846,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"am","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.therap.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T15:59:45Z","timestamp":1650470385000},"page":"509-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Management of drug-drug interactions with nirmatrelvir\/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)"],"prefix":"10.1016","volume":"77","author":[{"given":"Florian","family":"Lemaitre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bouchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Saint-Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Garraffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Guilhaumou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie-Pierre","family":"Jonville-Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Molimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patric","family":"Muret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2022.03.005_bib0185","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J"},{"key":"10.1016\/j.therap.2022.03.005_bib0190","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.therap.2022.03.005_bib0195","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.therap.2022.03.005_bib0200","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2022.03.005_bib0205","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/fcp.12586","article-title":"Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments","volume":"34","author":"Lemaitre","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.005_bib0210","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament. Thesaurus des interactions m\u00e9dicamenteuses. 2020. https:\/\/ansm.sante.fr\/documents\/reference\/thesaurus-des-interactions-medicamenteuses-1.[Accessed 18 March 2022]."},{"key":"10.1016\/j.therap.2022.03.005_bib0215","unstructured":"EMA. Paxlovid, Summary of products characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf.[Accessed 18 March 2022 (44 pp.)]]."},{"key":"10.1016\/j.therap.2022.03.005_bib0220","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/138920010794233521","article-title":"Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability","volume":"11","author":"Ancrenaz","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.therap.2022.03.005_bib0225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/cpt.1099","article-title":"Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel","volume":"105","author":"Itkonen","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2022.03.005_bib0230","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/ajt.13111","article-title":"Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir","volume":"15","author":"Badri","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.therap.2022.03.005_bib0235","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/FTD.0000000000000315","article-title":"Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct-acting antivirals as treatment for hepatitis C infection","volume":"38","author":"Badri","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2022.03.005_bib0240","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/bcp.14684","article-title":"Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: A physiologically based pharmacokinetic\/pharmacodynamic analysis","volume":"87","author":"Niu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.005_bib0245","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics","volume":"61","author":"Grimm","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.005_bib0250","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00042560-200006010-00007","article-title":"Differential impairment of triazolam and zolpidem clearance by ritonavir","volume":"24","author":"Greenblatt","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.therap.2022.03.005_bib0255","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1067\/mcp.2000.105757","article-title":"Alprazolam-ritonavir interaction: implications for product labeling","volume":"67","author":"Greenblatt","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2022.03.005_bib0260","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1592\/phco.29.10.1175","article-title":"Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe","volume":"29","author":"Schmitt","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2022.03.005_bib0265","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Johnson","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.therap.2022.03.005_bib0270","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00228-017-2403-3","article-title":"Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics","volume":"74","author":"Freise","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.005_bib0275","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/FTD.0000000000000761","article-title":"Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions","volume":"42","author":"Elens","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2022.03.005_bib0280","first-page":"305","article-title":"Managing drug-drug interaction between ombitasvir, paritaprevir\/ritonavir, dasabuvir, and mycophenolate mofetil","volume":"39","author":"Lemaitre","year":"2017","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.therap.2022.03.005_bib0285","doi-asserted-by":"crossref","first-page":"e00156","DOI":"10.1002\/prp2.156","article-title":"Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants","volume":"3","author":"de Jong","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.therap.2022.03.005_bib0290","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40261-013-0161-2","article-title":"Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir","volume":"34","author":"Wind","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.therap.2022.03.005_bib0295","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3851\/IMP1506","article-title":"Mutual pharmacokinetic interactions between bosentan and lopinavir\/ritonavir in healthy participants","volume":"15","author":"Dingemanse","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.therap.2022.03.005_bib0300","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00044011-200828080-00002","article-title":"Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study","volume":"28","author":"Sekar","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.therap.2022.03.005_bib0305","unstructured":"EMA. Ritonavir summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/norvir-epar-product-information_en.pdf.[Accessed 18 March 2022 (109 pp.)]]."},{"key":"10.1016\/j.therap.2022.03.005_bib0310","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cpdd.327","article-title":"Ombitasvir\/paritaprevir\/ritonavir and dasabuvir: drug interactions with antiretroviral agents and drugs forsubstance abuse","volume":"6","author":"King","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.therap.2022.03.005_bib0315","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00000542-199909000-00020","article-title":"Ritonavir's role in reducing fentanyl clearance and prolonging its half-life","volume":"91","author":"Olkkola","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1016\/j.therap.2022.03.005_bib0320","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2125.1998.00749.x","article-title":"Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers","volume":"46","author":"Ouellet","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.03.005_bib0325","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2022.03.005_bib0330","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2022.03.005_bib0335","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/17425255.2019.1685495","article-title":"Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV","volume":"15","author":"Cattaneo","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.therap.2022.03.005_bib0340","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1021\/js980197h","article-title":"Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo","volume":"87","author":"von Moltke","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.therap.2022.03.005_bib0345","doi-asserted-by":"crossref","first-page":"e01201","DOI":"10.1128\/AAC.01201-17","article-title":"Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport and the pharmacokinetic\/pharmacodynamic disposition of dabigatran","volume":"61","author":"Kumar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.therap.2022.03.005_bib0350","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00526-07","article-title":"Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.therap.2022.03.005_bib0355","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clpt.2006.04.014","article-title":"Lopinavir\/ritonavir reduces lamotrigine plasma concentrations in healthy subjects","volume":"80","author":"van der Lee","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2022.03.005_bib0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fphar.2016.00039","article-title":"Effects of amiodarone and N-desethylamiodarone on cardiac voltage-gated sodium channels","volume":"7","author":"Ghovanloo","year":"2016","journal-title":"Front Pharmacol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:14Z","timestamp":1758567314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595722000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0040595722000658"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.03.005","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of drug-drug interactions with nirmatrelvir\/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}